Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gopal, Gole"'
Autor:
Anand Tarage, Gopal Gole, Mandar Bhonde, Madhusudhan Reddy, Sharad Sharma, Harish Volam, Sudeep Sabde, Sanjeev Anant Kulkarni, Sadanand Mallurwar, Brahmam Sunkara, Ramesh Dattatraya Phadtare, Manoj Dandekar, Hemant Goyal, Samiron Phukan, Gayathri Sadasivam, Rupesh Kanhere, Maneesh Mehta, Nirmal Jana, Murthy Cheemala, Prashant Vidhate, Lal Dinchhana, Prashant B. Nigade, Bernstein Peter Robert, Prajakta Ahirrao, Rajan Goel, Aditya Naik, Vipul Pachpute, Sukanya Patra, Rajender Kumar Kamboj, Nilesh Mahajan, Kaustubh Tamane, Sneha Trivedi, M. K. Singh, Ajit Kumar Marisetti, Shankar Bhagwat, Mahip Verma, Atul Akarte, Dipak Lagad, Charudatt Samant, Venkata P. Palle, Vinod Patil, Anand Bokare, Dipak Modi, Chaitanya A. Kulkarni, Lakshmi Narasimham, Neetinkumar Reddy, Majid Bashir Sayyed, Sarita Koul, Shukla Manojkumar Ramprasad, Milind Gholve, Swati Tota, Vinod D. Chaudhari, Jayasagar Gundu, Manisha Shingare, Sachin J Mahangare, Shashikant Pawar
Publikováno v:
Journal of Medicinal Chemistry. 63:14700-14723
PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of the several important properties:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4614f9af4bf378b9f2f87f030837f97
https://doi.org/10.1021/acs.jmedchem.0c01264
https://doi.org/10.1021/acs.jmedchem.0c01264
Autor:
Manojkumar R, Shukla, Sukanya, Patra, Mahip, Verma, Gayathri, Sadasivam, Nirmal, Jana, Sachin J, Mahangare, Prashant, Vidhate, Dipak, Lagad, Anand, Tarage, Murthy, Cheemala, Chaitanya, Kulkarni, Shankar, Bhagwat, Vinod D, Chaudhari, Majid, Sayyed, Vipul, Pachpute, Ramesh, Phadtare, Gopal, Gole, Samiron, Phukan, Brahmam, Sunkara, Charudatt, Samant, Manisha, Shingare, Aditya, Naik, Sneha, Trivedi, Ajit Kumar, Marisetti, Madhusudhan, Reddy, Milind, Gholve, Nilesh, Mahajan, Sudeep, Sabde, Vinod, Patil, Dipak, Modi, Maneesh, Mehta, Prashant, Nigade, Kaustubh, Tamane, Swati, Tota, Hemant, Goyal, Harish, Volam, Shashikant, Pawar, Prajakta, Ahirrao, Lal, Dinchhana, Sadanand, Mallurwar, Atul, Akarte, Anand, Bokare, Rupesh, Kanhere, Neetinkumar, Reddy, Sarita, Koul, Manoj, Dandekar, Minakshi, Singh, Peter R, Bernstein, Lakshmi, Narasimham, Mandar, Bhonde, Jayasagar, Gundu, Rajan, Goel, Sanjeev, Kulkarni, Sharad, Sharma, Rajender Kumar, Kamboj, Venkata P, Palle
Publikováno v:
Journal of medicinal chemistry. 63(23)
PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of the several important properties:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9740bbdfcab4b764d76303bebfd167f6
https://pubmed.ncbi.nlm.nih.gov/33297683
https://pubmed.ncbi.nlm.nih.gov/33297683
Autor:
Albi Francis, Javed S. Shaikh, Tariq Bhat, Sanjay P. Kurhade, Nivrutti Kamble, Harish Volam, Sadanand Mallurwar, Pushpak Bora, Prashant B. Nigade, Mandar Bhonde, Hemant Goyal, Gagan Kukreja, Nishant R. Gupta, Nageswara Rao Irlapati, Prajakta Ahirrao, Bernstein Peter Robert, Rajesh B. Shankar, Kumar Ram Naik, Sneha Naidu, Gopal Gole, Yogesh Pawar, Apparao Bommakanti, Vinod Patil, Rajendra G. Powar, V.R. Praveen Kumar, Rakesh Kumar, Prabhakaran Kamalakannan, Anil K. Hajare, Neelima Sinha, Rajender Kumar Kamboj, Jayasagar Gundu, Sharad Sharma, Nilesh Khedkar, Arun R. Jagdale, Navnath P. Karche, Venkata P. Palle, Dipak Modi, Saif Wahid, Vamsi Pagdala, Kochumalayil Shaji George, Ganesh R. Jadhav, Gourhari Jana, Rohan Limaye, Baban Thube, Lakshmi Narasimham, Harshal Khanwalkar, Shashikant Pawar, Kumar V.S. Nemmani, Rajesh Gupta, Minakshi Singh, Ramesh Kale, Ajay R. Tilekar, Samiron Phukan, Dhananjay Bakhle, Pradipta Kumar
Publikováno v:
Bioorganic & Medicinal Chemistry. 28:115819
The exploitation of GLU988 and LYS903 residues in PARP1 as targets to design isoquinolinone (I & II) and naphthyridinone (III) analogues is described. Compounds of structure I have good biochemical and cellular potency but suffered from inferior PK.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae439561d9cd7678612504a2221cbc22
https://doi.org/10.1016/j.bmc.2020.115819
https://doi.org/10.1016/j.bmc.2020.115819